PTPN11 and cancer: Although phosphatases are generally thought to be negative regulators of signaling pathways involving protein kinases, several lines of evidence suggest that SHP2 promotes growth factor- and cytokine-induced Ras activation [39]; therefore, SHP2 has long been considered as a potential therapeutic target in cancer treatment.